Medication info
Pregaba Capsule 75 mg (Pregabalin)

Pregaba Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part, containing white powder
Packaging
(For domestic use) 30 capsules/bottle, 100 capsules/bottle (For export) 30 capsules (10 capsules x 3 PTP)
Approval status
Active

MFDS item code 201109155 · Approved 2011.10.25 · Insurance code 650302850

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is eliminated primarily by the kidneys; therefore, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Administration is not recommended in children under 12 years of age and adolescent patients aged 12-17 years because data on safety and efficacy are insufficient.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, regardless of the presence of secondary general symptoms. Additionally, it is effective in improving the symptoms of fibromyalgia. This helps manage various neurological disorders and pain, improving the quality of life for patients.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, regardless of food. This drug is eliminated primarily by the kidneys; therefore, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose of this drug may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Method of administration Initial dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Administration is not recommended in children under 12 years of age and adolescent patients aged 12-17 years because data on safety and efficacy are insufficient.

Precautions

This medication may increase the risk of suicidal thoughts or actions, so if symptoms of depression or mood changes occur during use, it is important to consult a doctor immediately. Patients who have allergies to any of the ingredients in this medication or certain genetic disorders should not use it. Diabetic patients should be cautious, as weight gain may necessitate adjustments in antidiabetic medication dosages. If allergic reactions such as angioedema occur, the medication should be discontinued immediately, and healthcare personnel should be informed. Elderly patients may be at risk of falling due to dizziness or drowsiness, and if such symptoms occur, they should consult with a healthcare provider. Vision disturbances or changes in sight may occur, so it is essential to report any eye issues immediately. Discontinuing this medication suddenly may lead to withdrawal symptoms like insomnia, headache, nausea, and anxiety; therefore, it should be tapered off according to the physician's instructions. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should be observed more closely. Patients with reduced kidney function may require dosage adjustments. Patients with heart disease should be cautious when taking this medication; if symptoms of heart failure occur, they must consult healthcare personnel immediately. Taking this medication with other central nervous system depressants or opioids may increase the risk of respiratory depression, so caution is necessary when used together. In early pregnancy, there is a risk of fetal malformation; thus, women who are pregnant or planning to get pregnant must consult a doctor and use effective contraceptive methods. Breastfeeding women should consult a physician regarding the potential transfer of the medication into breast milk and whether to discontinue breastfeeding or the medication. While driving or operating machinery, caution is needed due to the risk of accidents from dizziness and drowsiness until symptoms are fully assessed. Overdosage may result in symptoms such as confusion, drowsiness, and depression; therefore, the prescribed dosage must be strictly followed, and in the event of an overdose, immediate medical attention is required. Keep this medication out of the reach of children, and do not transfer it to another container for safety. If serious adverse reactions like skin rash, fever, or difficulty breathing occur while taking this medication, discontinue use immediately and seek emergency medical treatment.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 179 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • impaired respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • hypersalivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disturbances
  • incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • ejaculation delay
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • elevated blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • sense of relief
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood fluctuations
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • lack of inhibition
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • hypersomnolence
  • cognitive impairment
  • nystagmus
  • language disorder
  • tectonic muscle spasms
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • sensory hyperesthesia
  • burning sensation
  • action tremor
  • syncope
  • delirium
  • motor retardation
  • olfactory disturbances
  • loss of taste
  • writing impairment
  • diplopia
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • lingual swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • seizures
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to protect it from exposure to air or moisture, ideally at room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part, containing white powder

Package unit

(For domestic use) 30 capsules/bottle, 100 capsules/bottle (For export) 30 capsules (10 capsules x 3 PTP)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.